Biotronik GmbH launched the Lumax 540 series, which includes implantable cardioverter defibrillators (ICDs) and a cardiac resynchronization therapy defibrillator (CRT-D), which is used with Biotronik Home Monitoring to enable continuous automatic daily data transmission of the patient’s cardiovascular status.
The information is available to the physicians online allowing them to continuously check their patients’ cardiac and device status.
The Lumax 540 series has the SelectSense features, which has various presettings to adapt sensing characteristics to individual patient needs to ensure accurate arrhythmia detection. The Defibrillation Threshold Manager is to assure life-saving shock therapy delivered successfully. In addition, the Automatic Threshold Monitor performs daily threshold measurements. The Heart Failure Monitor detects changes in heart failure conditions with an extensive range of clinical predictors.
A comprehensive set of diagnostic capabilities are included in the Lumax 540 devices help physicians with the identification of clinically relevant atrial fibrillation and the early detection of worsening heart failure status. The Lumax 540 devices offer the unique combination of advanced tachycardia therapy management, diagnostic capabilities and remote monitoring technologies.
Biotronik’s extensive engineering research has produced industry-leading batteries, which are said to extend the life of the Lumax 540 devices up to 10 years.
February 12, 2024 
